Join us as we review and appraise recent practice-changing articles. In this episode, we cover the latest in GLP-1s and GIP agonists for CVD, Type 2 Diabetes, and Obesity, valacyclovir to treat Alzheimer’s, weight regain patterns after medication-induced weight loss, and a deep dive into the data behind deprescribing – and behavioral science to increase deprescribing behavior. Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Alex Chaitoff (@alexchaitoff), Nora Taranto (@norataranto), & Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Nora Taranto MD, MSCE; Alexander Chaitoff MD, MPH; Paul Williams, MD, FACP,, & Matthew Watto MD, FACP Cover Art: Nora Taranto MD, MSCE Reviewer: Sai S Achi MD, MBA, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer GLP-1 + GIPs vs GLP-1s for patients with T2DM and Obesity – SURPASS-CVOT Weight Regain after Weight loss VALAD – Valacyclovir in patients with early Alzheimer’s Nudges to increase Deprescribing Outro Sponsor: MedStudy Qbank Study less. Remember more. Pass confidently.Medstudy.com/CurbsidersCURB15 for 15% offSponsor: FIGSWe’ve teamed up with FIGS, and now Curbsiders listeners can get 15% off at Wearfigs.com with code FIGSRX. Sponsor: QuinceRight now, go to Quince.com/curb for free shipping and 365-day returns. Sponsor: A Dangerous DiagnosisTo get 20% off use DIAGNOSIS20 at www.penguinrandomhouse.com/books/808848/a-dangerous-diagnosis-by-shantanu-rai/paperback/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related